Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature
In late December 2019, a novel coronavirus (lately referred to as SARS-CoV-2) spread in the city of Wuhan, China, causing an outbreak of unusual viral pneumonia. In many people, the disease is mild and self-limiting, but in a considerable number of patients, the disease may present more severe or ev...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Healthcare |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9032/9/8/956 |
| _version_ | 1797523726530510848 |
|---|---|
| author | Mauro Giuffrè Luigi Vetrugno Stefano Di Bella Rita Moretti Debora Berretti Lory Saveria Crocè |
| author_facet | Mauro Giuffrè Luigi Vetrugno Stefano Di Bella Rita Moretti Debora Berretti Lory Saveria Crocè |
| author_sort | Mauro Giuffrè |
| collection | DOAJ |
| description | In late December 2019, a novel coronavirus (lately referred to as SARS-CoV-2) spread in the city of Wuhan, China, causing an outbreak of unusual viral pneumonia. In many people, the disease is mild and self-limiting, but in a considerable number of patients, the disease may present more severe or even fatal. Therefore, determining which patients are at higher risk of developing a more severe disease is critical. Some studies have been focused on serum and fecal calprotectin to evaluate COVID-19 disease progression and possible complications. Some assumptions can be made: (1) serum calprotectin may efficiently predict the prognosis of COVID-19 patients; (2) fecal calprotectin may appear high in COVID-19 patients due to the double hit mechanism to the intestine (inflammatory and ischemic); (3) a relationship between the complement system and neutrophil activation contributes to the procoagulant status seen in COVID-19 patients; (4) some patients may develop severe gastro-intestinal complications and fecal calprotectin can be used to monitor intestinal disease activity levels. |
| first_indexed | 2024-03-10T08:47:08Z |
| format | Article |
| id | doaj.art-b8c10979a6784bb98b0f37882ee7b840 |
| institution | Directory Open Access Journal |
| issn | 2227-9032 |
| language | English |
| last_indexed | 2024-03-10T08:47:08Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Healthcare |
| spelling | doaj.art-b8c10979a6784bb98b0f37882ee7b8402023-11-22T07:48:44ZengMDPI AGHealthcare2227-90322021-07-019895610.3390/healthcare9080956Calprotectin and SARS-CoV-2: A Brief-Report of the Current LiteratureMauro Giuffrè0Luigi Vetrugno1Stefano Di Bella2Rita Moretti3Debora Berretti4Lory Saveria Crocè5Department of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, ItalyDepartment of Medicine, Anesthesia and Intensive Care Clinic, University of Udine, 33100 Udine, ItalyDepartment of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, ItalyDepartment of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, ItalyDebora Berretti—Gastroenterology Unit, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, ItalyDepartment of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, ItalyIn late December 2019, a novel coronavirus (lately referred to as SARS-CoV-2) spread in the city of Wuhan, China, causing an outbreak of unusual viral pneumonia. In many people, the disease is mild and self-limiting, but in a considerable number of patients, the disease may present more severe or even fatal. Therefore, determining which patients are at higher risk of developing a more severe disease is critical. Some studies have been focused on serum and fecal calprotectin to evaluate COVID-19 disease progression and possible complications. Some assumptions can be made: (1) serum calprotectin may efficiently predict the prognosis of COVID-19 patients; (2) fecal calprotectin may appear high in COVID-19 patients due to the double hit mechanism to the intestine (inflammatory and ischemic); (3) a relationship between the complement system and neutrophil activation contributes to the procoagulant status seen in COVID-19 patients; (4) some patients may develop severe gastro-intestinal complications and fecal calprotectin can be used to monitor intestinal disease activity levels.https://www.mdpi.com/2227-9032/9/8/956fecal calprotectincalprotectinCOVID-19SARS-CoV-2IBD |
| spellingShingle | Mauro Giuffrè Luigi Vetrugno Stefano Di Bella Rita Moretti Debora Berretti Lory Saveria Crocè Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature Healthcare fecal calprotectin calprotectin COVID-19 SARS-CoV-2 IBD |
| title | Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature |
| title_full | Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature |
| title_fullStr | Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature |
| title_full_unstemmed | Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature |
| title_short | Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature |
| title_sort | calprotectin and sars cov 2 a brief report of the current literature |
| topic | fecal calprotectin calprotectin COVID-19 SARS-CoV-2 IBD |
| url | https://www.mdpi.com/2227-9032/9/8/956 |
| work_keys_str_mv | AT maurogiuffre calprotectinandsarscov2abriefreportofthecurrentliterature AT luigivetrugno calprotectinandsarscov2abriefreportofthecurrentliterature AT stefanodibella calprotectinandsarscov2abriefreportofthecurrentliterature AT ritamoretti calprotectinandsarscov2abriefreportofthecurrentliterature AT deboraberretti calprotectinandsarscov2abriefreportofthecurrentliterature AT lorysaveriacroce calprotectinandsarscov2abriefreportofthecurrentliterature |